Migraine is a disabling primary headache disorder that directly affects more than one billion
people worldwide. Despite its widespread prevalence, migraine remains under-diagnosed …

Chronic migraine is a neurologic disorder associated with considerable disability, lost
productivity, and a profound economic burden worldwide. The past five years have seen a …

Introduction Despite advances in the management of headache disorders, some patients
with migraine do not experience adequate pain relief with acute and preventive treatments. It …

Background erenumab was safe and effective in clinical trials for the prevention of migraine.
However, real-life data are still lacking. Here we report the clinical experience from an Italian …

Introduction Gender equity and gender medicine are opportunities not to be missed, and this
Expert Group Opinion Paper on pain in women aims to review the treatment of pain …

Introduction and objective Monoclonal antibodies targeting the calcitonin gene-related
peptide pathway (anti-CGRP mAbs) have shown promising efficacy in randomised clinical …

Introduction Migraine prophylactic therapy has changed over recent years with the
development and approval of monoclonal antibodies (mAbs) targeting the calcitonin gene …

Botulinum toxin A (BTA) is widely used as treatment of chronic migraine. Efficacy in studies,
however, was only modest and likely influenced by unblinding due to BTA-induced removal …

Botulinum toxin type A has been used in the treatment of chronic migraine for over a decade
and has become established as a well-tolerated option for the preventive therapy of chronic …

Background. Migraine is one of the most common types of headache, and it is the second
most common cause of neurological disorders, with an annual prevalence of about 15% of …